PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is commonly used in the clinic to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST); it is an inhibitor that targets BCR-ABL kinase, c-Kit receptor, and PDGFR.